Macter International Launches Semaglutide in Pre-Filled Syringe and Pen Formats

PAKISTAN

In accordance with Section 96 and 131 of the Securities Act, 2015 and Clause 5.6.1 of the Pakistan Stock Exchange Rule Book, Macter International Limited has announced the successful launch of Semaglutide in Pre-Filled Syringe (PFS) and Pre-Filled Multi-Dose Pen (PFP) presentations.

Semaglutide, a Glucagon-Like Peptide-1 (GLP-1) receptor agonist, is a cutting-edge biotechnology drug widely used for the management of Type 2 Diabetes Mellitus and increasingly recognized for its efficacy in weight management and metabolic health.

With this latest launch, Macter International has become the only company in Pakistan to offer Semaglutide across all three biotechnology dosage formats — Vials, Pre-Filled Syringes, and Pre-Filled Pens.

Macter Int’l Secures Licenses for Advanced Biotech Facilities

This milestone represents a significant step forward in the company’s Biotech portfolio, strengthening its position as a pioneer in delivering advanced and globally competitive therapies to patients in Pakistan.

Macter stated that this achievement reflects its ongoing commitment to improving access to innovative treatments and enhancing the quality of healthcare in the country. – ER News Desk

READ MORE NEWS